Personalized Cancer Therapy Considering Cytochrome P450 Variability

Area of Science:

• Pharmacogenomics
• Oncology
• Drug Metabolism

Background:

• Individual pharmacokinetic variability is often underestimated, leading to adverse drug reactions or ineffective treatments, especially in polychemotherapy.
• Prodrugs like ifosfamide require activation by cytochrome P450 enzymes (CYPs), and patient variations in these enzymes can determine therapeutic success.
• The role of CYPs and transporters in target tissues, and their potential overexpression, is frequently overlooked in clinical practice.

Purpose of the Study:

• To highlight the significance of individual variability in drug pharmacokinetics and metabolism.
• To present a comprehensive body map illustrating the distribution of relevant drug-metabolizing enzymes across organs and tissues.
• To discuss the application of personalized cancer therapy by considering genetic variations.

Main Methods:

• Review of existing literature on pharmacokinetic variability and cytochrome P450 enzymes.
• Development of a body map detailing enzyme distribution in various tissues.
• Case study analysis of a breast cancer patient undergoing chemotherapy.

Main Results:

• Pharmacokinetic variability significantly influences drug efficacy and toxicity, particularly for CYP-activated prodrugs.
• A body map visualizing tissue-specific enzyme expression was created.
• Genotyping revealed single nucleotide polymorphisms in a breast cancer patient, informing personalized treatment strategies.

Conclusions:

• Personalized cancer therapy, informed by genetic profiling and understanding of drug-metabolizing enzymes, is crucial for optimizing chemotherapy outcomes.
• Addressing individual pharmacokinetic differences can mitigate side effects and improve treatment effectiveness.
• Further research into tissue-specific enzyme expression and its clinical implications is warranted.